Status:
COMPLETED
Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study
Lead Sponsor:
The University of Hong Kong
Conditions:
Nephrosis, Lipoid
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syn...
Detailed Description
This is a prospective, open-label, randomized study in which patients who present for the first time with a clinical diagnosis of idiopathic MCNS proven on renal biopsy will be assigned to either conv...
Eligibility Criteria
Inclusion
- Male or female 18 - 65 years of age
- First histologic diagnosis of MCNS
- Proteinuria \> 3.5 g/day
- Patients who are willing to give written, informed consent
Exclusion
- Presence of secondary causes of MCNS
- History of glomerular disease including MCNS
- eGFR \< 50 ml/min/1.73m2
- Renal histology showing pathologies other than MCNS
- Female of child-bearing age who are unwilling to practice effective contraception
- Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01185197
Start Date
September 1 2010
End Date
June 1 2017
Last Update
June 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, China